drugset / Trial / NCT06658951
Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
Recruiting
30 enrolled
UTC Therapeutics Inc.
The First Affiliated Hospital of Zhengzhou University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-HER2 CAR-T cell injection in patients with HER2-positive advanced malignant solid tumors.
Timeline
- Start
- 2025-04-03
- Primary completion
- 2027-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-HER2 CAR-T cells | Cell therapy | — | — |
Indications
No indication recorded.